NIMS’ Exer-Rest acceleration therapeutic platform awarded Japanese patent

Non-Invasive Monitoring Systems, Inc. [NIMS] (OTCBB:NIMU) announced that the Nogawa Patent Office in Japan issued Patent number 4391595 to NIMS on October 16, 2009. This patent, entitled “Reciprocating Movement Platform for Shifting Subject To and Fro In Headwards-Footwards Direction,” relates to the comprehensively researched technology underlying NIMS’ Exer-Rest acceleration therapeutic platform. This patent expires on March 18, 2018.

Dr. Marvin A. Sackner, NIMS’ Founder and CEO noted that, “this Japanese Patent is a counterpart to US Patent 6,155,976, first issued for this technology in the year 2000. We are excited about completing this first step towards entering Japan and we are currently evaluating a number of options to commence our Japanese marketing, sales and distribution activities.”

Steven Mrha, COO added that, “NIMS’ high quality, commercial strength and multipurpose Exer-Rest is suitable for both rehabilitation facility and home use. For individuals that find it difficult to exercise or have become sedentary, having a means to stay active is extremely important in reducing secondary risks associated with lack of mobility. The Exer-Rest is a wonderful solution and can be used by individuals of all capabilities.”

Exer-Rest is currently being marketed and sold in the United States, Canada and other major international markets. It has been cleared by the FDA as an aid to temporarily increase local circulation, to provide temporary relief of minor aches and pains, to reduce morning stiffness and to provide local muscle relaxation. The Exer-Rest is also approved in Europe as an aid for increasing joint mobility. NIMS is currently seeking similar regulatory clearance to market the Exer-Rest in Japan.

Source:

Non-Invasive Monitoring Systems, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics